{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-002703","form_type":"8-K","ticker":"ALUR","cik":"0001964979","company_name":"ALLURION TECHNOLOGIES, INC.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.388924+00:00","generated_at":"2026-06-07T02:39:28.874578+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Allurion prelim 2023 rev $53-54M, cuts 30% staff, 2024 outlook $60-65M","bullets":["Full-year 2023 revenue expected $53-54M; gross margin 77-78%; procedural volume up 30% YoY.","Q4 2023 revenue expected $8.1-8.3M; European procedural volume grew 44% in Q4 vs prior year.","Cash balance $38M as of Dec 31, 2023; Q4 cash burn $22M; term loan reduced by $20M to $40M.","Reduced headcount ~30% since Dec 2023 to cut quarterly cash burn to $7-8M in 2024.","2024 outlook: revenue $60-65M, procedural volume growth ~20%, gross margins 77-79%; FDA pivotal trial readout (AUDACITY) expected by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-002703","json":"https://secwatch.observer/filing/0000950170-24-002703.json","markdown":"https://secwatch.observer/filing/0000950170-24-002703.md","text":"https://secwatch.observer/filing/0000950170-24-002703.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1964979/000095017024002703/0000950170-24-002703-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1964979/000095017024002703/alur-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:39:28.874578+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"16825f33351f042d40dd5320161ce32984de9be5","claim":"ALLURION TECHNOLOGIES, INC. reported the fiscal year ended December 31, 2023 results: revenue $53 - $54 million.","evidence_excerpt":"2023 full year revenue is expected to be in the range of $53 - $54 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1964979/000095017024002703/0000950170-24-002703-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Revenue","value":"$53 - $54 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"17886d9cd8aba8d33f914242959aa7003856af1a","claim":"ALLURION TECHNOLOGIES, INC. reported the quarter ended December 31, 2023 results: revenue $8.1 - $8.3 million.","evidence_excerpt":"Fourth quarter revenue is expected to be in the range of $8.1 - $8.3 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1964979/000095017024002703/0000950170-24-002703-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2023"},{"label":"Revenue","value":"$8.1 - $8.3 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"87b1cfb4970e2da0a86fe96400d3ca9799b13235","claim":"ALLURION TECHNOLOGIES, INC. reported fiscal year 2024 results: revenue $60 - $65 million. Guidance initiated.","evidence_excerpt":"24 Outlook • Anticipated procedural volume growth of approximately 20%, despite a reduction in overall marketing spend, reflecting increased penetration in key direct markets and reallocation of marketing spend to more efficient channels • Revenue guidance of $60 - $65 million , reflecting growth of approximately 13% - 23% year over year • Expected gross margins of 77-79%, reflecting durable pricing of our gastric balloon as well as initial commercialization efforts of the digital platform • Targeted cash burn reduced to approximately $7 - $8 million per quarter Key 2024 Growth Catalysts • Accelerated procedure volume growth across direct markets where Allurion has fully established direct sales and support models • Release of new clinical data, including the AUDACITY FDA pivotal trial read-out expected by end of year, and additional data validating Allurion’s best-in-class weight loss a","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1964979/000095017024002703/0000950170-24-002703-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2024"},{"label":"Revenue","value":"$60 - $65 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}